News Releases

Taiho Pharmaceutical's news releases are intended to provide information to the media. It may contain information about ethical drugs or products under development, however information contained in the news releases are not intended to constitute promotion, advertisement, or medical advice.

Site search

2022

December 13, 2022

Otsuka Group Selected for CDP Climate Change A List（PDF：374.3 KB）
November 24, 2022

Taiho Pharmaceutical Obtains Additional Indication of "Postoperative Adjuvant Chemotherapy for Hormone Receptor-Positive and HER2-Negative Breast Cancer at High Risk of Recurrence" for Oral Anticancer Agent TS-1
October 06, 2022

Taiho Pharmaceutical Adds New Measures to Reduce Smoking Among Employees to Zero by 2023
October 03, 2022

U.S. FDA Approves FGFR Inhibitor, Futibatinib for the Treatment of Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma
September 13, 2022

Drug Combination Meets Survival Endpoint in Phase III Pivotal Trial Involving Participants With Refractory Metastatic Colorectal Cancer（PDF：316.4 KB）
August 30, 2022

Taiho Pharmaceutical Launches Solmack_® Q-Arl S, a New Addition to the Solmack Line of Products for Skin Problems and Hangover Tiredness Associated with Malnutrition
August 30, 2022

Mild Mint Flavored Remedy for Bad Breath "PITAS Cool Troche M" Launched on August 30 Through Taiho Pharmaceutical Healthcare Online Shop
August 30, 2022

Taiho Pharmaceutical Launches HSP90 Inhibitor Jeselhy_® Tablets 40 mg (Pimitespib)
July 29, 2022

PITAS Throat Troche Series Now Available Outside Japan - To Ease Your Throat Discomfort Without Being Noticed
July 28, 2022

Taiho Pharmaceutical Submits New Drug Application of FGFR inhibitor futibatinib (TAS-120) for Biliary Tract Cancer
July 01, 2022

Taiho Pharmaceutical to Provide Matching Funds to Select Crowdfunded Projects Addressing Issues in the Field of Oncology the Second "Taiho Smile Support"
June 20, 2022

Taiho Pharmaceutical Obtains Approval to Manufacture and Market HSP90 inhibitor Jeselhy_® Tablets 40 mg (Pimitespib) for Gastrointestinal Stromal Tumor (GIST)
June 01, 2022

Taiho Pharmaceutical to Donate a Total of 4.17 Million Yen to Three Projects Addressing Issues in the Field of Oncology "The First Taiho Smile Support"
May 25, 2022

Taiho Pharmaceutical Announces the Launch of Selective NK₁ Receptor Antagonist Arokaris_® I.V. Infusion 235mg in Japan
May 12, 2022

Taiho Pharmaceutical and Cullinan Oncology Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taiho's Acquisition of Cullinan Pearl （PDF：139.2 KB）
April 21, 2022

Otsuka Group Joins RE100 International Initiative　- Committed to 100% Renewable Energy -
March 30, 2022

U.S. FDA Accepts for Priority Review New Drug Application of Futibatinib for Advanced Cholangiocarcinoma（PDF：199.0 KB）
March 28, 2022

Taiho Pharmaceutical Obtains Approval to Manufacture and Market NK₁ Receptor Antagonist Arokaris^® I.V. Infusion 235mg in Japan（PDF：101.2 KB）
March 01, 2022

Taiho Pharmaceutical Launches Harncare Bearberry Tablets ー Helping to Improve the Discomfort When Urinating and Sensation of Residual Urine
March 01, 2022

Taiho Pharmaceutical Launches PITAS Cool Troche S, a Remedy for Bad Breath That Can be Used Anytime, Anywhere
February 14, 2022

Taiho Pharmaceutical Applies for Additional Indication of "Postoperative Adjuvant Chemotherapy in Breast Cancer"for Oral Anticancer Agent TS-1 Based on POTENT Study (Advanced Medical Care B/Specific Clinical Research) Results
February 01, 2022

Taiho Pharmaceutical Certified as a Sports Yell Company by the Japan Sports Agency in Recognition of Its Provision of Opportunities for Exercise Tailored for New Lifestyles

News Releases

Select year from the Back Number